Occupational Activity – Page 6

Novo Nordisk Appoints New CEO and Reduces 2025 Sales Guidance

5 months ago talkbio0Tagged CEO, Changing, drug competition, growth outlook, guidance cut, Leadership, Maziar Mike Doustdar, Nordisk, Obesity, Sales - occupational activity, Transition Mutation

Novo Nordisk; CEO change; Maziar Mike Doustdar; 2025 sales guidance cut; growth outlook; leadership transition; obesity drug competition

Novo Nordisk Names Insider Maziar Mike Doustdar as New CEO Amid Growth Challenges

5 months ago talkbio0Tagged Appointments, CEO, Drug Industry, drug market, growth outlook, international operations, Leadership Change, Maziar Mike Doustdar, Nordisk, Obesity

Novo Nordisk; Maziar Mike Doustdar; CEO appointment; leadership change; pharmaceutical industry; growth outlook; obesity drug market; international operations

Galapagos Considers Sale of Cell Therapy Unit in Ongoing Strategic Overhaul

5 months ago talkbio0Tagged Business Development, Cell Therapy, Galapagos, Gilead Sciences, GLPG5101, Mantle cell lymphoma, pipeline, Sales - occupational activity, strategic alternatives

Galapagos; cell therapy; sale; strategic alternatives; pipeline pruning; biotech; spinout; Gilead Sciences; GLPG5101; mantle cell lymphoma; business development

CDMO Pulse Check: Lonza Posts Major Sales Rebound as Samsung Bio Keeps Revenue Growth Rolling

5 months ago talkbio0Tagged capsule (pharmacologic), CDMO, commercial, expansion, Growth, Lonza, Manufacturing, profit margin, Sales - occupational activity, Samsung Bio

Lonza; CDMO; sales growth; Samsung Bio; 2025 outlook; profit margin; Capsules & Health Ingredients; commercial momentum; manufacturing expansion

Bayer Extends CEO Bill Anderson’s Contract; Sarepta C-Suite Turmoil

5 months ago talkbio0Tagged Bayer, Bill Anderson, C-suite changes, CEO, company transformation, contract extension, Pharma, restructuring

Bill Anderson; Bayer; CEO contract extension; company transformation; restructuring; Sarepta; C-suite changes; pharma industry

Biopharma Layoffs Continue to Surge in First Half of 2025

5 months ago talkbio0Tagged Biopharma, biotech closures, Increase, Industry, layoffs, trends qualifier

biopharma; layoffs; 2025; workforce reductions; industry trends; biotech closures; year-over-year increase

UnitedHealth Group Names Mike Cotton as New Medicaid CEO in Executive Reshuffle

5 months ago talkbio0Tagged Appointments, Bobby Hunter, CEO, executive changes, Gossypium, government programs, Leadership, Medicaid, UnitedHealth Group

UnitedHealth Group; CEO appointment; Medicaid; Mike Cotton; executive changes; government programs; Bobby Hunter; leadership transition

Vor Bio’s $4B+ Revival Deal for RemeGen’s Autoimmune Drug Triggers Divergent Stock Moves

6 months ago talkbio0Tagged Autoimmune Diseases, CEO, Changing, Myasthenia Gravis, PIPE financing, RemeGen, Stock Reaction, Vor Bio

Vor Bio; RemeGen; telitacicept; autoimmune disease; $4 billion deal; myasthenia gravis; stock reaction; CEO change; PIPE financing

Bavarian Nordic Sells FDA Priority Review Voucher for $160M Amid Rising Industry Prices and Program Scrutiny

6 months ago talkbio0Tagged Bavarian Nordic, biotech finance, chikungunya vaccine, NIH Mouse, Priority Review, Sales - occupational activity, United States Food and Drug Administration, Vimkunya

Bavarian Nordic; Priority Review Voucher; FDA; voucher sale; $160 million; chikungunya vaccine; VIMKUNYA; NIH; antitrust review; biotech finance

Lark Health Launches LarkVantage: AI-Powered Platform to Manage GLP-1 Costs

6 months ago talkbio0Tagged Administration occupational activities, Artificial Intelligence, authorization, cost management, Gibbs, Glucagon-Like Peptide 1, Health care facility, Health Planning, Lark Health, LarkVantage, Pharmacy Benefit Manager, utilization qualifier, Weight maintenance regimen

Lark Health; LarkVantage; GLP-1 cost management; AI healthcare; prior authorization; utilization management; PBM; health plans; weight management; Matthew Gibbs